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Context: Hyperprolactinemia-induced hypogonadotropic amenorrhea (hPRL-HA) is a major
cause of hypothalamic gonadotrophin-releasing hormone (GnRH) deficiency in women. In
hyperprolactinemic mice, we previously demonstrated that hypothalamic kisspeptin (Kp) ex-
pression was diminished and that Kp administration restored hypothalamic GnRH release, go-
nadotropin secretion, and ovarian cyclicity, suggesting that Kp neurons could also play a role in
hPRL-HA.
Objective: To study the effect of Kp-10 on the gonadotropic-ovarian axis in women with hPRL-HA.
Patients: Two women (32 and 36 years old) with chronic hPRL-HA (prolactin: between 94 and 102 and
98 and 112 ng/mL, respectively) caused by cabergoline-resistant microprolactinomas.
Interventions: Cabergoline was discontinued 6 months before inclusion. Blood samples were taken
every 10 minutes for 12 hours during 2 consecutive days to evaluate luteinizing hormone (LH) and
follicle-stimulating hormone (FSH) secretion. Serum estradiol (E2), testosterone (T), and inhibin B (IB)
levels were also measured. Vehicle or Kp-10 (1.5 mg/kg/h) was infused intravenously for 12 hours.
Results:Kp-10 induced a significant increase in LHandFSH levels and increased LHpulses. E2, T, and
IB serum levels were also significantly increased.
Conclusions: In this exploratory study, we demonstrated that administration of Kp-10 reactivated
gonadotropin secretion in women with hPRL-HA and increased ovarian activity. Our data suggest that,
as in rodents, GnRH deficiency in hPRL-HA is also mediated by an impairment of hypothalamic Kp
secretion. Kp-10 or its analogues could have therapeutic application as an alternative approach to
restore ovarian function and fertility in women with hPRL-HA resistant to dopamine agonists and in
whom pituitary surgery is not possible.
This article has been published under the terms of the Creative Commons Attribution License (CC
BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in anymedium, provided the original author and source are credited. Copyright for this
article is retained by the author(s).
Abbreviations: CV, coefficient of variation; E2, estradiol; FSH, follicle-stimulating hormone; GnRH, gonadotrophin-releasing hor-
mone; hPRL, hyperprolactinemia; hPRL-HA, hyperprolactinemia-induced hypogonadotropic amenorrhea; IB, inhibin B; Kp, kiss-
peptin; LH, luteinizing hormone; NKB, neurokinin B; PRL, prolactin; PRLR, prolactin receptor; T, testosterone.
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Hyperprolactinemia (hPRL) is a well-established and frequent cause of hypogonadotropic
hypogonadism inwomen andmen and is one of themain etiologies of anovulatory infertility in
premenopausal women [1–5]. However, the precise mechanism whereby prolactin inhibits
pituitary gonadotropin secretion is still unclear in humans [1, 2].
The combined luteinizing hormone (LH) and follicle-stimulating hormone (FSH) de-
ficiencies associated with hPRL were first proposed to result from a direct effect of prolactin
(PRL) on gonadotrophin-releasing hormone (GnRH) neurons, leading to a decrease in GnRH
release [1, 2, 6]. This hypothesis was supported by the demonstration that pulsatile GnRH
replacement reversed both hypogonadotropic hypogonadism and infertility in women and
men with hPRL [7–9]. This further suggested that PRL excess in humans affects hypotha-
lamic release of GnRH rather than directly affecting pituitary or gonadal function [1, 2, 6–9].
An unresolved question is whether elevated PRL directly affects GnRH neurons via PRL
receptors (PRLRs) or indirectly affects GnRH neurons by acting upstream on other interme-
diate neurons that regulate GnRH secretion. Because very few GnRH neurons express PRLRs
[10–13], the latter suggestion appears more likely. It is now well established that GnRH
neurons are stimulated by kisspeptin (Kp) neurons and that Kp neurons unequivocally express
PRLRs [14, 15]. Furthermore, we demonstrated in a female mouse model of hypogonadotropic
anovulation induced by hPRL that hypothalamic Kp expression was diminished but that of
neurokinin B (NKB) was not and that peripheral Kp administration could restore GnRH
and gonadotropin secretion and ovarian cyclicity [16]. These results as well as the observation
of reduced hypothalamic Kp expression during lactation-induced hPRL in mice strongly
supported the notion that Kp plays a role in mediating hPRL-induced anovulation in mice
[11, 12]. In the current exploratory study, we explored whether diminished Kp might underlie
hPRL-induced hypogonadotropic amenorrhea (hPRL-HA) in women. To shed light on this, we
determined whether Kp administration could reactivate the gonadotropic axis in women with
hPRL-HA.
1. Patients and Methods
Two premenopausal women with amenorrhea caused by PRL microadenomas were included
in this exploratory study. Patients 1 and 2 were 32- and 36-year-old women with 6 to
11 months of secondary amenorrhea and galactorrhea. Serum PRL levels ranged from 94 to
102 ng/mL and from 98 to 112 ng/mL in patient 1 and patient 2, respectively (normal range,
9.0 to 20 ng/mL). Estradiol (E2) levels were low, and serum gonadotropins were low or in-
appropriately normal, indicating hPRL-HA (Table 1) [1, 2]. Pituitary magnetic resonance
imaging revealed microadenomas that were 5 and 6 mm in diameter in patients 1 and 2,
respectively. Neither of these patients had other pituitary hormone deficiencies or excesses at
diagnosis (normal free T4, thyroid stimulating hormone, insulin-like growth factor-1, normal
cortisol and growth hormone responses to hypoglycemic challenge, and normal urinary free
cortisol) (Table 1). Administration of cabergoline at doses of 2 to 3 mg per week for 5 and
7 months in patients 1 and 2, respectively, did not result in a decrease in circulating PRL
concentrations, which were 100 and 102 ng/mL, or a decrease in prolactinoma size, which was
5 mm and 6.5 mm, respectively, after treatment. Cabergoline was discontinued because of a
failure to respond 6 months before patient inclusion. At the time of the study, neither patient
was taking any medication. No menstrual bleeding had occurred during or after cabergoline
discontinuation, although galactorrhea persisted.
A. Protocol
Kp-10 was custom-synthesized under Good Manufacturing Practices standards (Bachem
GmbH,Weil am Rhein, Germany) and aliquoted in vials as described previously [17–20]. The
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lyophilizedKp-10was reconstituted in 5mLof sterile physiological saline as previously described
[17]. The Paris Sud University and Biceˆtre Hospital ethics committees approved the study (CPP
Ile-de-France VII, Biceˆtre Hospital, and ANSM ID RCB: 2017-A02140-53), and the two par-
ticipants gave their informed consent. Subjects were admitted to the hospital at 08:00 hours for
12 hours of blood sampling every 10 minutes for 2 consecutive days as previously described [17].
Vehicle (physiological saline) or Kp-10 in saline (1.5 mg/kg/h) was infused intravenously from 08:
30 to 20:30 hours on days 1 and 2, respectively; randomization was not performed because of the
possibility of Kp-102induced activity confounding results during vehicle infusion. There were no
adverse events related to Kp-10 infusion, as previously reported [17–20].
B. Hormone Assays
Serum PRL level was measured by immunofluorescence using Time Resolved Amplified
Cryptate Emission (TRACE™) technology with a Brahms KRYPTOR™ platform (Thermo
Fisher, Hennigsdorf, Germany). The detection limit was 0.1 ng/mL. The intra-assay coefficient
of variation (CV) was 3.5%. In both patients, sera were treated with polyethylene glycol to
exclude measurement of macroprolactin [21]. Serum FSH and LH levels were measured using
sensitive immunoradiometric assays (CIS bio international, GIF sur Yvette, France) as re-
ported [22], with a detection limit of 0.05 IU/L for both hormones (IU/L, second International
Reference Preaparation World Health Organization 78/549 for FSH; IU/L, first IRP 68/40 for
LH). The intra-assay CV was 1.5% for LH and 2.7% for FSH using quality control sera
measuring 3.5 and 3.9 IU/L, respectively [22]. Serum inhibin B (IB) levels weremeasured with
the Beckman Coulter Gen II assay (Marseilles, France), with a detection limit of 3 pg/mL and
intra-assay CVs of 6% at 15 pg/mL [22]. Serum E2 and testosterone were assayed in a single
batch in all samples using gas chromatography/mass spectrometry, as described in detail by
Giton et al. [23]. The lower limits of detection and the intra-assay CVwere 2.4 pg/mL and 7.9%,
respectively, for E2 using quality control serum. The lower limits of detection and the intra-
assay CV were 0.05 ng/mL and 2.2% for testosterone (T).
Table 1. Main Features of Two Patients With Prolactin-Secreting Microadenomas at Diagnosis
Patient 1 (P1) Patient 2 (P2) Normal Range
Age, y 32 36 —
Menstrual cycle Amenorrheaa Amenorrheab Regular (27–32 days)
Galactorrhea Yes Yes —
Microadenoma at pituitary MRI 5-mm diameter intrasellar 6-mm diameter intrasellar —
Prolactin, ng/mL 94–102c 98–112c 9–20
FSH, IU/L 4.2 4.9 (3.1–7.6)d
LH, IU/L 3.9 2.1 (2.9–7.8)d
Estradiol, pg/mL 21 17 (22–97)d
Progesterone, ng/mL 0.2 0.3 (4.9–14.4)e
Inhibin B, pg/mL 49 28 (29–126)d
Cortisol, ng/mLe 108/265f 124/209f (89–220)/(198–336)f
Free T4 (pmol/L)/TSH (mIU/L) 16.8/2.7 15.2/1.9 (10.4–21)/(0.6–4.4)
IGF1, mg/L 273 232 (169–311)g
DHEAS, ng/mL 1954 1386 (679–3993)g
To convert estradiol in pg/mL to pmol/L, multiply by 3.671. To convert the prolactin values in ng/mL to mIU/L,
multiply by 21.3. For DHEAS, to convert ng/mL to nmol/L, multiply by 2.714.
Abbreviations: DHEAS, dehydroepiandrosterone sulfate; FT4, free thyroxine; IGF1, insulin-like growth factor-1;
MRI, magnetic resonance imaging; TSH, thyroid stimulating hormone.
aSince 6 months.
bSince 11 months.
cRange (different measures and after exclusion of macroprolactinemia).
dIn the early follicular phase.
eIn the normal luteal postovulatory phase.
fBasal/peak under hypoglycemia challenge test.
gIn healthy 30- to 40-year-old women.
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C. Statistical Analysis
Pulses were detected by the Thomas algorithm by analysis of LH concentrations in samples
collected at 10-minute intervals [24, 25]. Mean serum LH and FSH levels during infusion of
vehicle (n = 72 measurements of each gonadotropin) or Kp-10 (n = 72 measurements of each
gonadotropin) were compared in each of the patients with the paired nonparametricWilcoxon
test. In the two patients, mean serum IB levels (n = 12measurements during each treatment)
and mean serum E2 levels (n = 12) were compared with the paired nonparametric Wilcoxon
test. P values ,0.05 were considered statistically significant.
2. Results
Kp-10 was well tolerated, and no adverse side effects were found in this study as in previous
studies using this regimen of dose and treatment duration [17–20].
A. Gonadotropins
Circulating LH and FSH concentrations and pulsatility during 12-hour vehicle or Kp-10
(1.5 mg/kg/h) infusions in patients 1 and 2 are shown in Fig. 1. A significant increase in
circulating LH levels was observed in both patients during Kp-10 infusion. In patient 1, four
significant LH pulses were detected during vehicle administration by the Thomas algorithm
[24, 25], whereas five were detected during Kp-10 infusion (Fig. 1A). In this patient, mean
serum LH levels increased from amean6 standard deviation of 5.36 2.9 IU/L during vehicle
Figure 1. Secretory pattern of LH and FSH during infusion of saline (vehicle) or kisspeptin-
10 (Kp-10) in two female patients (P1 and P2) with hyperprolactinemia-induced hypogonadotropic
amenorrhea. Asterisks and open circles denote LH pulses as identified by the Thomas
algorithm while the patients were receiving Kp-10 and vehicle, respectively [24, 25]. See
also Table 2. During vehicle administration, serum prolactin levels were between 108 and
111 ng/mL in P1 and between 112 and 129 ng/mL in P2. During Kp-10 infusion, serum
prolactin levels were between 103 and 114 ng/mL in P1 and between 116 and 120 ng/mL in
P2. Area under the curve values are depicted in the histograms.
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administration to 25.46 10.8 IU/L (P, 0.0001) during Kp-10 infusion (Table 2). In patient 2,
two significant LH pulses were detected during vehicle infusion vs three during Kp-10 ad-
ministration (Fig. 1B), and mean serum LH levels increased significantly (P , 0.0001) from
1.22 6 0.43 IU/L during vehicle infusion to 5.2 6 2.4 IU/L during Kp-10 infusion (Table 2).
Circulating FSH concentrations were also significantly higher (P , 0.0001) in the two pa-
tients during Kp-10 infusion than during vehicle infusion (Fig. 1C and 1D; Table 2).
B. Ovarian Hormones
Circulating E2, T, and IB concentrations during 12-hour vehicle or Kp-10 (1.5 mg/kg/h) in-
fusions in patients 1 and 2were significantly increased duringKp-10 infusion (Fig. 2; Table 2).
3. Discussion
hPRL is a common cause of hypogonadotropic hypogonadism in men and women and one of
the leading causes of anovulatory infertility (WHO Group I) in premenopausal women [1–5].
However, the precise mechanism underlying the association has not been fully elucidated.
The proposal that LH and FSH deficiencies associated with hPRL are mediated by a direct
inhibitory effect of PRL on GnRH neurons was supported by the demonstration that
recombinant PRL administration suppressed pulsatile endogenous LH secretion in healthy
women [6] and that pulsatile GnRH replacement can reverse hypogonadotropic hypo-
gonadism and restore fertility in women and men with hPRL [7–9]. This observation also
suggests that PRL effects are not directly on the pituitary or gonads. Although the findings
indicated that PRL effects were mediated by an inhibition of GnRH secretion, they did not
resolve whether elevated PRL level directly affects the GnRH neurons or whether this action
is mediated by an inhibition of upstream neurons, such as Kp and NKB, which stimulate
GnRH secretion [1, 16, 17]. The latter possibilities appeared more likely because very few
GnRH neurons expressed PRLRs [10, 14]. On the other hand, Kp neurons, which also express
NKB in the arcuate nucleus, were particularly cogent targets for hPRL effects, as they ro-
bustly expressed PRLRs in laboratory rodents [10]. Moreover, we demonstrated that in a
female mousemodel of hypogonadotropic anovulation induced by continuous infusion of PRL,
hypothalamic Kp messenger RNA and protein were diminished, whereas there was no effect
on NKB encoding gene expression [16]. Furthermore, peripheral Kp-10 administration re-
stored GnRH and gonadotropin secretion and ovarian cyclicity [16]. We therefore reasoned
Table 2. LH, FSH, Estradiol, Testosterone, and Inhibin B Concentrations in Women With
Hyperprolactinemia Receiving Vehicle (Saline) and Then Kp-10 Infusion
Patient 1 (P1) Patient 2 (P2)
Normal
RangeaSaline Kp-10 Saline Kp-10
LH, IU/L 5.3 6 2.9 (n = 72) 25.4 6 10.8b (n = 72) 1.226 0.43 (n = 72) 5.2 6 2.37b (n = 72) 2.2–8.2
FSH, IU/L 3.6 6 0.3 (n = 72) 12.1 6 4.3b (n = 72) 5.5 6 1.0 (n = 72) 12.2 6 2.7b (n = 72) 2.4–7.9
Estradiol, pg/mL 18.6 6 4.5 (n = 12) 47.5 6 20.9c (n = 12) 16.8 6 1.9 (n = 12) 24.7 6 8.6d (n = 12) 18–97
Testosterone, ng/mL 0.786 0.04 (n = 12) 0.92 6 0.08c (n = 12) 0.626 0.02 (n = 12) 0.696 0.02c (n = 12) 0.3–0.8
Inhibin B, pg/mL 50.5 6 5.7 (n = 12) 188.06 69.4b (n = 12) 28 6 2.4 (n = 12) 40.9 6 6.4c (n = 12) 29–129
Data are presented asmean6 standarddeviation.During saline control andKp-10, 12measurements of estradiol and
inhibin B were performed. To convert estradiol in pg/mL to pmol/L, multiply by 3.671. To convert testosterone values
in ng/mL to nmol/L, multiply by 3.467.
aNormal values were taken from the early follicular phase, days 3 to 6 after onset of menses; data from 51 healthy
women [22].
bP , 0.0001 (Wilcoxon test).
cP , 0.01 (Wilcoxon test).
dP , 0.05 (Wilcoxon test).
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Figure 2. Effect of vehicle or Kp-10 administration on circulating estradiol, testosterone,
and inhibin B levels in the two patients (P1 and P2) with hyperprolactinemia-induced
hypogonadotropic amenorrhea. See also Table 2.
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that the same mechanism might underlie hPRL hypogonadotropic hypogonadism in humans
and that Kp-10 administration would restore gonadotropin levels and ovarian activity.
To examine this proposal, we recruited two women with lactotrope microadenomas that
were resistant to cabergoline therapy and who had chronically elevated PRL levels and
secondary amenorrhea with galactorrhea, reduced or inappropriately normal gonadotropins,
and lowE2 levels. Both patients showed robust elevations of LH, FSH, E2, and IB. Ideally, we
would have included more subjects in the study, but these patients are difficult to recruit
because resistance to cabergoline therapy (i.e., failure to normalize PRL levels) inwomenwith
PRL microadenomas is rare [2, 26, 27]. We therefore felt that the results were sufficiently
clear-cut to advance knowledge in the area.
Although Kp-10 robustly increased serum concentrations of gonadotropins, E2, T, and IB,
it is uncertain that this would be maintained in chronic administration. We have shown in
mice exposed to continuous PRL that ovarian cycles and oocyte development can be restored
by single daily doses of Kp-10 [16], suggesting the treatment will be effective in patients with
hPRL. This suggestion is supported by the observation that twice-daily administration of Kp-
54 did not affectmenstrual cyclicity and did not abolish acute stimulation of LHafter injection
of Kp-54 or GnRH [28].
In both patients, the rise in LH and FSH levels continued for about 8 hours of Kp-10
infusion; however, thereafter both gonadotropins declined but were still considerably higher
than levels during vehicle infusion. This decline could be due to desensitization to Kp-10
(tachyphylaxis). However, we and others have not seen desensitization in humans over this
time frame [17], even after 32 hours of continuous infusion at this dose [19]. It is therefore
more likely that the rising E2 and IB levels were responsible for this decline in FSH and LH
values through physiological negative feedback. It is also pertinent that the current study
used continuous infusion, whereas in the therapeutic setting, single daily doses would be
administered as was efficacious in our mouse studies. Moreover, as mentioned earlier, in
healthy women twice-daily injection of Kp for 5 days did not abolish acute stimulation of LH
after injection of Kp-54 [28]. A similar protocol would be used for women with hPRL and the
reasonable expectation of follicular development and ovulation. Because elevated PRL levels
in ourmousemodel decreased Kp gene and protein expression without affectingNKB, the use
of Kp-10 to restore fertility to hPRL would appear to be more physiological than use of GnRH
or gonadotropins. Indeed, Kp has been used to safely and effectively stimulate oocyte mat-
uration in women at high risk of developing ovarian hyperstimulation syndrome who were
undergoing IVF treatment [29], and Kp-10 restored T to normal levels in men with diabetes
mellitus [19].
On a cautionary note, previous reports have shown that stimulation with hypothalamic
trophic hormones in patients with existing pituitary adenomas may in rare cases result in
bleeding within the adenoma [30]. The infusion of Kp in the two patients described here was
well tolerated. There was no episode suggestive of pituitary necrosis, either during or after Kp
administration, as indicated by the absence of headache or visual disturbances. In addition,
hypophyseal magnetic resonance imaging performed in both patients a few months after the
infusion showed no evidence of adenoma necrosis or hemorrhage. Mean PRL levels remained
elevated in both patients, suggesting that there was no adenomatous necrosis or hemorrhage.
Overall, Kp-10 was well tolerated, and no adverse side effects were found in this study, as in
previous studies using this dose regimen and treatment duration [17–20].
The findings in the current study suggest that the site of action of PRL is at the Kp neuron
because an action at the GnRH neuron would have prevented or at least diminished GnRH/
gonadotropin responses to Kp-10, whereas the LH and FSH responses were rapid and very
substantial (four- to fivefold for LH, which is greater than LH responses to Kp-10 in healthy
women) [20]. It is plausible, however, that PRL action is at the level of NKB secretion in
humans, as we have shown robust stimulation of gonadotropins by Kp-10 in patients with
NKB and NKB receptor2inactivating mutations [17] and in healthy women receiving an
NKB antagonist [18, 31], suggesting that NKB action is upstream of Kp. Thus, if PRL in-
hibition of gonadotropins is at the level of NKB, this would result in decreased endogenous Kp
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secretion and a robust response to Kp-10, as we found in our patients. In our studies on mice
rendered anovulatory by continuous PRL infusion, there was a decrease in Kp and GnRH
messenger RNA and protein but no change in NKB [16], suggesting that the effect of PRL is
not at the level of NKB, at least not in laboratory mice. It might be possible to tease out the
level of effect of hPRL in humans by examining gonadotropin response to NKB agonists (e.g.,
senktide) [18, 31]. If responses to senktide are sluggish, we could interpret that the site of
action of PRL is at the level of Kp diminution; however, if the effect is robust, it would suggest
that elevated PRL operates by inhibiting NKB.
Patient 1 exhibited a high LH/FSH ratio in contrast to patient 2, who had a higher FSH/LH
ratio. This may be due to a higher GnRH pulse frequency in patient 1, which favored LH
secretion [32]. Patient 1 had six LH pulses compared with three pulses in patient 2. Patient 1
appeared to have more advanced follicular development and a higher E2 level after Kp-10,
which may account for higher pulse frequency resulting from positive feedback; however,
further speculation is unjustified in a study with only two patients.
The elevation in gonadotropins by Kp-10 was accompanied by an increase in E2 and IB to
levels similar to those found in the follicular phase of themenstrual cycle of healthywomen. This
suggests that Kp-10 induced the release of bioactive gonadotropins and that antral follicular
development had been initiated in the two patients with hPRL-HA. Our results suggest the
possibility of utilizing Kp-10 or analogues for induction of ovulation in womenwith elevated PRL
levels from microadenomas that are unresponsive to dopamine agonists [27] and in women
undergoing neuroleptic/antipsychotic therapy but desiring pregnancy and unable to tolerate
antipsychotic drug withdrawal [33]. From a therapeutic viewpoint, Kp therapy in this setting
may have advantages over alternative conventional treatments. GnRH therapy requires pul-
satile administration of the medication by a portable pump, which is quite restrictive. Gonad-
otrophin administration requires tight ovarian monitoring to avoid ovarian hyperstimulation.
Treatment with Kp is more physiological and potentially more convenient, as previous studies
have shown that twice-daily subcutaneous injection is effective [28].
There is also evidence that E2 can have a protective effect in schizophrenic psychoses [30],
thus suggesting that in patients with hPRL who are taking antipsychotics, elevation of E2 by
Kp may benefit their mental state in addition to restoring fertility [33, 34].
In conclusion, this study demonstrated that Kp-10 can restore gonadotropin levels and
ovarian function in women with hPRL-HA. The inhibitory effects of PRL on the gonadotrope
axis appeared to be mediated through Kp-secreting neurons, as in rodents.
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